Sentences with phrase «positive early breast cancer»

My translational research has focused on trying to find better ways to estimate recurrence risk in patients diagnosed with oestrogen - receptor positive early breast cancer, with the ultimate aim to better personalise our therapies for those patients who have the most to gain from them.

Not exact matches

The MINDACT study is managed and sponsored by the EORTC in collaboration with the Breast International Group (BIG) and included 6,693 women with early stage breast cancer (lymph node negative or 1 - 3 lymph node posiBreast International Group (BIG) and included 6,693 women with early stage breast cancer (lymph node negative or 1 - 3 lymph node posibreast cancer (lymph node negative or 1 - 3 lymph node positive).

The findings provide the highest level of evidence supporting expert - derived clinical practice guidelines which have recommended Oncotype DX in patients with early stage ER - positive breast cancer.

When factoring in what is now known about breast cancer biology and heterogeneity, breast conserving therapy (BCT) may offer a greater survival benefit over mastectomy to women with early stage, hormone - receptor positive disease, according to research from The University of Texas MD Anderson Cancer Ccancer biology and heterogeneity, breast conserving therapy (BCT) may offer a greater survival benefit over mastectomy to women with early stage, hormone - receptor positive disease, according to research from The University of Texas MD Anderson Cancer CCancer Center.

«This study demonstrates that Prosigna can reliably identify early stage breast cancer patients who have a low risk - of disease recurrence at 10 years, including a substantial proportion of patients with node - positive disease for whom the risk / benefit derived for adjuvant chemotherapy would be at best neutral,» said Dr. Alessandra Cesano, chief medical officer of NanoString Technologies.

PALLAS: Palbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR +) / Human Epidermal Growth Factor Receptor 2 (HER2)- Negative Early Breast Cancer

In an article published in the Journal of Clinical Oncology (https://doi.org/10.1200/JCO.2017.74.6586), Laenkholm et al report on a study of 2,558 postmenopausal women identified as having HR positive / HER2 - negative, early - stage breast cancer, 1,395 of whom had one to three positive axillary nodes.

«These results have driven us to update our treatment guidelines in Denmark to include testing with Prosigna as part of the workup of postmenopausal women with early stage HR - positive / Her -2 negative breast cancer, including patients with node - positive disease.»

FDA approves trastuzumab (Herceptin) for use with other drugs in the adjuvant treatment of women with early - stage node - positive HER2 - overexpressing breast cancer.

FDA approves the aromatase inhibitors anastrozole and exemestane for the adjuvant treatment of hormone receptor - positive early - stage breast cancer.

Further investigation into what triggers immunosuppressive phenotypes in early - stage HER2 - positive breast cancers with residual disease is warranted.»

SEATTLE, Feb. 05, 2018 (GLOBE NEWSWIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the publication of a landmark study in which Danish researchers used the Prosigna ® Breast Cancer Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andBreast Cancer Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andCancer Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andcancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andbreast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andcancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 and 2003.

Though trastuzumab and pertuzumab have increased response rates and improved outcomes in HER2 - positive breast cancer, 30 % to 40 % of early - stage patients treated in the neoadjuvant setting will have residual disease at the time of surgery.

The authors built a statistical simulation model to estimate the 25 - year incremental costs per quality - adjusted life - year (QALY) for Oncotype DX testing in order to evaluate the cost - effectiveness of GEP testing among patients with early - stage ER - positive / HER2 - negative breast cancer treated in community oncology practices.

The trial included 2,176 patients with early - stage HER2 - positive breast cancer and randomly assigned them to 9 - weeks trastuzumab or 12 - months trastuzumab.

«Our data suggest that early - stage HER2 - positive breast cancers treated with neoadjuvant combination docetaxel, carboplatin, and trastuzumab with or without pertuzumab demonstrate tumor immune microenvironment phenotype changes,» the authors concluded.

[jounal] Sears, S. R. / 2003 / The yellow brick road and the emeraldcity: Benefit finding, positive reappraisal coping and posttraumatic growth in women with early - stage breast cancer / Health Psychology 22 (5): 487 ~ 497

The Foundation funds initiatives that support and advocate for: relevant and innovative research; meaningful education and awareness programs; early diagnosis and effective treatment; and a positive quality of life for those living with breast cancer.